News Health Economics Before the Trial: Why Early HTA Should Shape MedTech Development by Odelle Technology November 7, 2026 The most valuable health-economic model may be the one that changes the development programme before the pivotal study begins. Odelle Technology | November 2026 Core argument: health economics should not …
Podcast Podcast with Alastair Hick, Chief Executive Officer, Uniseed by Odelle Technology September 28, 2026 In this episode of the Global Healthcare Innovation Podcast Steven Haken has an interesting discussion with Alastair Hick, the CEO of Uniseed, an Australian venture fund focused on university research commercialisation. …
News How France’s New MiMED Unit Could Change Health Technology Assessment by Odelle Technology September 27, 2026 On 23 July 2026, France’s Haute Autorité de Santé announced the creation of MiMED — Mission Méthodes, Europe, Données. MiMED is an expansion of the Cellule de coordination des données …
News How to Optimize Cost-Effectiveness: Kaplan-Meier curve by Odelle Technology September 27, 2026 What reconstructed patient-level survival data can and cannot tell us Odelle Technology | September 2026 A Kaplan-Meier curve is not merely a picture. It contains enough structured information that, under …
News When Treatment Never Starts by Odelle Technology September 6, 2026 What metastatic pancreatic cancer reveals about patient choice, real-world evidence and the denominator Two contemporary datasets appear to describe radically different treatment uptake in metastatic pancreatic cancer: 72% untreated in …
News How Biotech Can Win Reimbursement in Spain After EU JCA 2027 by Odelle Technology September 5, 2026 What Spain’s new HTA system means for biotech reimbursement after European Joint Clinical Assessment Europe has harmonised part of the clinical assessment. It has not harmonised reimbursement. Spain’s Real Decreto …
Reimbursement Belgium EEFA: A Biotech Reimbursement Guide for Early & Fast Access by Odelle Technology September 5, 2026 For a small biotech, the most expensive word in European market access is often not “no”. It is “later”. Belgium’s new Early and Equitable Fast Access (EEFA) pathway aims to …
News France’s Revised Early Access Framework: What Biotech Companies Need to Know About Reimbursement by Odelle Technology September 5, 2026 France has not launched a new early-access scheme. It has changed the operating rules of an established route that can place innovative medicines into funded clinical use before conventional reimbursement …
News How the NHS Is Rewriting the Economics of Antimicrobial Resistance by Odelle Technology August 14, 2026 Why Britain’s subscription model is trying to make antimicrobial stewardship compatible with pharmaceutical innovatio There is something economically strange about a good antibiotic. We want it to exist. We may …
News How to Get AI Reimbursed in Germany – and Why G-BA’s “Shadow AI” Investigation Changes the Evidence by Odelle Technology August 9, 2026 A practical, evidence-led guide to DiGA, G-BA methods assessment, §137e evidence generation, hospital NUB funding, §137h high-risk device assessment and the emerging problem of undocumented AI inside “usual care”. Editorial …